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The overall prognosis for oesophageal squamous cell carcinoma is
still poor, with 5-year survival of 5–45% (Lerut et al, 1992; Ide et
al, 1994; Roder et al, 1994). Some factors are thought to influence
survival, such as sex, stage, microscopic grade, DNA ploidy,
epidermal growth factor receptor (EGFR), p53 and lymph node
metastasis (Rosai, 1996). Several studies using multivariate
analysis indicated that lymph node metastasis is a strong indepen-
dent prognostic factor (Theunissen et al, 1991; Roder et al, 1994;
Tanigawa et al, 1997). We previously reported that the expression
of vascular endothelial growth factor (VEGF) is associated
with lymph node metastasis and prognosis in oesophageal cancer
(Uchida et al, 1998). Other reports showed that the expression
of matrix metalloproteinases (MMPs) (Shima et al, 1992),
E-cadherin (Kadowaki et al, 1994; Nakanishi et al, 1997) and p53
(Wang et al, 1994) in primary tumours correlated with lymph node
metastasis of oesophageal cancer.
From the aspect of therapy, angiogenesis-mediators and MMPs
have been the recent focus of anti-cancer therapy (Gastl et al,
1997). If we are to use anti-angiogenesis drugs or MMP inhibitors
as either adjuvant therapy after surgery or therapy for recurrent
tumours, we will clearly require more information regarding the
expression of angiogenesis-mediators and MMPs in metastatic
tumours. However, few studies describe the expression of these
proteins in lymph node metastasis. Therefore, the question
remains: do cancer cells continue to express these factors in the
lymph nodes?
Previous investigators have described several steps in the
metastatic process (Liotta, 1992; Chambers and Matrisian, 1997).
In the process of lymph node metastasis, sequential steps after
entry into lymph node would include the following: adhesion to
the endothelium of the peripheral sinus, invasion to the
parenchyma of the lymph node and sustained growth of cells in the
lymph node. What is not yet known, however, is whether the
expression of VEGF, MMPs and E-cadherin in cancer cells is
changed during these steps of lymph node metastasis.
To answer these questions, we compared the immunohisto-
chemical expression of VEGF, MMP-9, E-cadherin and p53, not
only between primary tumours and lymph node metastases of
oesophageal cancer, but also between the Early Stage and Late
Stage of lymph node metastasis (for a definition of staging see
Materials and Methods).
MATERIALS AND METHODS
Samples
We obtained 134 primary tumour samples from 134 patients with
oesophageal squamous cell carcinomas from April 1984 to
September 1996 treated in the Department of Surgery and Surgical
Basic Science, Kyoto University. We divided 134 primary tumour
samples into two groups. Group N(–) (n = 37) were resected from
patients without synchronous lymph node metastasis or nodal
recurrence in follow-up period (³ 2 years), and Group N(+)
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(n = 97) were from patients with lymph node metastasis, including
one pN0 case with metachronous nodal metastasis.
We obtained 174 lymph node metastasis samples from 35
patients selected from Group N(+). We classified 174 lymph node
metastases into two groups, according to the space occupation rate
of cancer cells in the maximum cross-section of lymph node
(Figure 1). There were 56 nodal metastases classified as Early
Stage (cancer cells < 50% of lymph node) and 118 metastases
classified as Late Stage (³ 50%). To detect micro-metastasis
within the lymph node and to estimate the distribution of cancer
cells accurately, we used both haematoxylin and eosin (H&E) stain
and anti-cytokeratin immunohistochemistry.
Antibodies
We used five different antibodies, against VEGF, MMP-9,
E-cadherin, p53 and cytokeratin. A rabbit polyclonal antibody to
VEGF was a generous gift from Dr Ishiwata (Department of Joint
Disease, Nippon Medical School, Tokyo, Japan) (Nagashima et al,
1995). A mouse monoclonal antibody (HECD-1) directed against
E-cadherin was a kind gift from Dr Takeichi (Department of
Biophysics, Faculty of Science, Kyoto University, Kyoto, Japan).
This antibody was used as a 1:100 dilution of culture supernatant
of the hybridoma clone described previously (Shimoyama et al,
1989). The three other mouse monoclonal antibodies were
commercially available: anti-hMMP-9 (clone 56-2A4, Fuji
Chemical Industries, Ltd, Takaoka, Japan), anti-p53 (clone DO-7,
Dako A/S, Glostrup, Denmark), and anti-cytokeratin (clone
AE1/AE3, Dako A/S, Glostrup, Denmark). The reliability of the
three antibodies has been described elsewhere (Woodcock
Mitchell et al, 1982; Vojtesek et al, 1992; Kawahara et al, 1993).
Immunohistochemistry
The tissue samples were fixed in 10% buffered formalin and
embedded in paraffin. Paraffin sections were cut at a thickness of
4-mm and attached to APS-coated glass slides. Sections were
dewaxed, hydrated and treated using a high temperature antigen
retrieval technique (microwave heating for VEGF and p53, and
autoclave heating for MMP-9, E-cadherin and cytokeratin). The
endogenous peroxide was blocked with 0.3% hydrogen peroxide
in absolute methanol for 30 min. Thirty minutes of incubation with
10% normal horse serum or 10% normal goat serum eliminated
non-specific staining. Excess normal serum was removed,
replaced by the primary antibody overnight at 4°C. After washing
the slides, sections were incubated with a 1:200 dilution of
secondary antibody followed by avidin–biotin–peroxidase
complex (Vecstain Elite ABC Kit, Vector Laboratories, Inc.,
Burlingame, CA, USA) for 40 min or 50 min respectively.
Subsequently, sections were stained with 0.003% 3,3-diamino-
benzidine tetrahydrochloride, 0.005% hydrogen peroxide in
0.05 M Tris–HCl buffer, pH 7.2, counterstained with Mayer’s
haematoxylin, dehydrated and mounted.
Early-Stage
Lymph node metastasis
Late-Stage
Cancel cells < 50% of lymph node Cancer cells ³ 50% of lymph node
Figure 1 A schema of the staging of lymph node metastasis. We decided
on the stages of lymph node metastasis according to space occupation rate
of cancer cells in the maximum cross section. When cancer cells occupied
less than 50% of the lymph node, the sample was termed ‘Early Stage’.
When cancer cells occupied more than 50% of lymph node, it was termed
‘Late Stage’
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Figure 2 The expression of VEGF, MMP-9, E-cadherin and p53 in primary
tumour and lymph node metastasis. (A) The expression of Group N(–)
(n = 37) and Group N(+) (n = 97) in primary tumour. (B) The expression in
Early Stage (n = 56) and Late Stage (n = 118) of lymph node metastasis. *:
Fisher’s exact probability test1368 F Sato et al
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Evaluation of immunohistochemical staining
VEGF staining was classified into two groups: negative and
positive, as previously described (Uchida et al, 1998). Shima et al
(1992) classified the stains of MMPs in oesophageal cancer into
three groups. We, however, classified MMP-9 staining into two
groups to simplify the data: negative, when the intensity of stain in
cancer cells was negative or weaker than normal oesophageal
epithelia; positive, when the intensity of staining was equal to or
stronger than normal epithelia. According to estimates of positive-
staining cell rates, E-cadherin and p53 were divided into two
groups: preserved (³ 50%) and reduced (< 50%), negative (< 10%)
and positive (³ 10%) respectively.
Histology and staging
Histological evaluations were based on the TNM classification
proposed by the International Union against Cancer in 1997
(UICC, 1997).
Statistical analysis
Proportional analysis between sample groups was performed with
the c2 test with Yates’ correction and Fisher’s exact probability test
in 2 ´ 2 contingency tables. All tests were two-sided, and results
were considered significant when P < 0.05.
RESULTS
Expression of VEGF, MMP-9, E-cadherin and p53 in
primary tumours
VEGF expression correlated with lymph node metastasis: 48.6%
in Group N(–), 74.2% in Group N(+). E-cadherin expression was
classified as reduced in 76.3% of Group N(+), compared with
51.4% of Group N(–). This demonstrates the relationship between
reduction of E-cadherin in primary tumours and lymph node
metastasis. With regard to MMP-9 expression in primary tumours,
Table 1 Clinicopathological background of patients with and without lymph node metastasis
Group N(–) Group N(+) Total P-value
Gender
Male 25 85 110
Female 12 12 24 P = 0.014
Age
Range (years) 46–84 39–84 39–84
Mean±s.d. 65.2±10.1 62.7±10.0 63.4±10.0 P = 0.202
TNM classification
pTis 2 0 2
pT1 20 13 33
pT2 6 23 29 P < 0.0001
pT3 5 43 48
pT4 4 18 22
pN0 37 1a 38
pN1 0 96 96
pM0 37 59 96
pM1 0 38 38
(M1a; 16, M1b; 20)
Stage
02 0 2
I2 0 0 2 0
IIa 11 1 12
IIb 0 21 21
III 4 37 41 P < 0.0001
IV 0 38 38
(IVa; 16, IVb; 20)
Differentiation gradeb
GX 3 0 3
G1 (well) 8 13 21
G2 (moderate) 16 52 68 P = 0.383
G3 (poor) 10 32 42
Group N(–); patients without synchronous lymph node metastasis or nodal recurrence in follow-up period (³2 years), Group N(+), patients with lymph node
metastasis, including one N0 case with metachronous nodal metastasis. aGroup N(+) includes a N0 case with metachronous lymph node metastasis. bIn three
cases, grade of differentiation could not be assessed because almost all or all lesions were limited in epithelia (two; Tis, one; T1).
Table 2 Inter-nodal heterogeneity of VEGF, MMP-9, E-cadherin and p53
Early-stage (%) Late-stage (%) Overall (%)
VEGF 8/15 (53.3) 11/23 (47.8) 17/28 (60.7)
MMP-9 2/15 (13.3) 8/23 (34.8) 12/28 (42.9)
E-cadherin 7/15 (46.7) 12/23 (52.2) 16/28 (57.1)
p53 5/15 (33.3) 5/23 (21.7) 7/28 (25.0)Lymph node metastasis in oesophageal cancer 1369
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we found no statistical difference between Group N(–) and N(+).
The expression of p53 tended to be enhanced in Group N(+), but
this was not significant (Figure 2).
Expression of VEGF, MMP-9, E-cadherin and p53 in
lymph node metastases
VEGF expression in lymph node metastasis is down-regulated
with the development of the metastatic tumour. VEGF-positive
staining decreased from 60.7% in Early Stage to 33.1% in
Late Stage. MMP-9 expression was up-regulated only in Early
Stage. The MMP-9-positive rate is elevated to 94.6% in
Early Stage, and returns to 68.6% – similar to the level observed
in primary tumour.
E-cadherin expression is restored in Early Stage, but suppressed
again in Late Stage. The expression of p53 was enhanced in Late
Stage relative to Early Stage, but this was not significant.
Employing anti-cytokeratin immunohistochemistry, we found
micro-metastases in 17 lymph nodes, which had been diagnosed as
normal by usual pathological examination using H&E staining.
Among these metastases, we were able to evaluate the expression
of VEGF, MMP-9, E-cadherin and p53 in nine lymph node metas-
tases of seven patients: VEGF (7/9), MMP-9 (8/9), E-cadherin
(5/9) and p53 (2/9). The expression of VEGF, MMP-9 and
E-cadherin in micro-metastases were roughly consistent with that
observed in Early Stage metastasis.
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Clinicopathological background of patients
Patients studied consisted of 110 males and 24 females. The age of
patients ranged from 39 to 84 (mean ± standard deviation (s.d.):
63.4 ± 10.0). Gender and pT-factor correlated with lymph node
metastasis, but not differentiation grade or age (Table 1). With
regards to the clinicopathological background and the expression
of VEGF, MMP-9, E-cadherin and p53, we found no differences
between patients selected from Group N(+) in the examination of
lymph node and the others (data not shown).
Localization of VEGF, MMP-9, E-cadherin and
cytokeratin staining
VEGF stained the vesicle of cancer cells. Immunoreactivity
against MMP-9 was found in the basal layers of normal
oesophageal epithelia, macrophages, granulocytes, fibroblasts and
the cytoplasm of cancer cells. E-cadherin expression was detected
only in the cytomembrane, or both in the cytomembrane and the
cytoplasm of cancer cells, and in the cytomembrane of normal
epithelia.
This anti-cytokeratin antibody (AE1/AE3) recognizes many
types of cytokeratin. Staining was detected in the cytoplasm of
cancer cells and normal oesophageal epithelia. The staining of the
cancer cells was intense and covered almost the entire cells in all
but one of the 35 patients whose lymph nodes were examined.
Heterogeneity between lymph node metastases
Frequently, patients with cancer have plural lymph node metas-
tases. To ascertain whether all lymph node metastasis of a patient
express equal amounts of VEGF, MMP-9, E-cadherin or p53, we
compared the expression of these proteins among the metastases of
each patient. The number of lymph node metastases obtained from
the same patient ranged from 1 to 19 (mean ± s.d.: 4.74 ± 4.08).
Fifteen patients had plural lymph node metastases in Early Stage,
whereas 23 patients had Late Stage plural metastases.
Table 2 shows the number of these patients with inter-nodal
heterogeneity of VEGF, MMP-9, E-cadherin and p53 expression
(i.e. patients whose metastases varied with respect to the expres-
sion of these proteins). A high rate of overall inter-nodal hetero-
geneity is expected because the expression of VEGF, MMP-9 and
E-cadherin changes from Early Stage to Late Stage. However, we
found inter-nodal heterogeneity of expression of all four factors in
each stage, ranging from 13.3% to 53.3%.
DISCUSSION
The question addressed by the present study was whether the
expression of VEGF, MMP-9, E-cadherin and p53 remains stable,
or changes in the process of lymph node metastasis of oesophageal
cancer. The main finding of this study is that the expression of
VEGF, MMP-9, E-cadherin and p53 changes not only between the
primary tumour and lymph node metastasis, but also between
early- and late-stages of lymph node metastasis.
The pattern of change is different for each of these factors in the
process of lymph node metastasis, and suggests where each factor
might play an important role in the metastatic process. The pattern
of VEGF is that VEGF expression of Group N(+) is much greater
than that of Group N(–); however, the expression of VEGF is
suppressed with the progression of metastatic stage. We and other
investigators showed that over-expression of VEGF in primary
tumours correlates with lymph node metastasis in oesophageal
cancer and other tumours (Maeda et al, 1996; Moriyama et al,
1997; Ohta et al, 1997; Uchida et al, 1998). VEGF is a multi-
functional molecule that has been implicated in vasculogenesis
(Carmeliet et al, 1996; Ferrara et al, 1996), endothelial cell prolif-
eration and migration (Senger et al, 1993), vascular permeability
(Roberts and Palade, 1995), and stromal degradation through the
activation of some proteolytic enzymes involved in tumour inva-
siveness and angiogenesis (Ferrara, 1996). However, it is not yet
known which of VEGF’s functions play an important role in
promoting lymph node metastasis. On the other hand, it is gener-
ally believed that angiogenesis is required in secondary tumour
progression (Folkman, 1990). Our data shows that in Early Stage
metastasis VEGF is prominent when compared to Late Stage, and
suggests that development in Late Stage tumour growth may be
VEGF-independent, whereas the initial metastatic event may be
VEGF-dependent or at least correlative.
The pattern of MMP-9 expression is that the MMP-9-positive rate
is elevated in Early Stage of lymph node metastasis, whereas MMP-
9 expression in primary tumour (both Group N(–) and N(+)) and
Late Stage lymph node metastasis is lower. In our data, MMP-9
expression in primary tumour does not correlate with lymph node
metastasis or any other clinicopathological factors (data not shown).
The balance of activators and inhibitors, such as TIMP-1, regulates
activity of MMP-9 (Liotta and Stetler Stevenson, 1991). In Early
Stage metastatic lymph nodes, lymphocytes or macrophages
Figure 3 Staining of VEGF, MMP-9, E-cadherin and p53 in lymph node
metastasis. (A–D) Positive staining of VEGF, MMP-9, E-cadherin and p53
(A: VEGF, B: MMP-9, C: E-cadherin, D: p53). (E–H) Staining of
micrometastasis in the same region (E: cytokeratin, F: VEGF, G: MMP-9,
H: E-cadherin) (all: 200 ´). Arrowhead: stained cancer cells
G
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surrounding cancer cells also produce MMP-9, and constitute a
greater volume than do the metastatic cells. Therefore, it is unknown
whether MMP-9 produced by cancer cells disturbs the balance
between proteinases and inhibitors. However, our present findings
suggest that cancer cells in Early Stage may react more strongly to a
new microenvironment than cancer cells in Late Stage.
The pattern for E-cadherin is that the suppression of E-cadherin
expression in primary tumour correlates with lymph node metas-
tasis, and this result is compatible with findings of numerous other
studies. In metastatic lesion, E-cadherin expression tends to be
somewhat restored in Early Stage, but suppressed again in Late
Stage. Cell dissociation and acquisition of cell motility are
believed to affect the initial steps in the metastatic process.
Therefore, suppressed expression or dysfunction of the
cadherin–catenin complex might trigger the escape of cancer cells
from the primary tumour. E-cadherin expression in metastatic
lesion has been described by several authors, and became some-
what controversial (Schipper et al, 1991; Bongiorno et al, 1995;
Jawhari et al, 1997; von Wasielewski et al, 1997). Shiozaki specu-
lates that unstable E-cadherin reduction plays a role in terms
of detachment and release from the primary lesion in the process
of vessel invasion; however, when it comes to the establishment of
actual metastasis, the opposite appears to be more favourable from
the standpoint of attachment and growth as metastatic foci
(Shiozaki et al, 1996). Our data also suggest that E-cadherin
expression might offer some advantages in Early Stage of lymph
node metastasis.
In this study, p53 expression was unchanged from Early Stage
to Late Stage, whereas VEGF, MMP-9 and E-cadherin was down-
regulated. These data indicate that the down-regulation of VEGF,
MMP-9 and E-cadherin expression does not depend on non-
specific reduction of overall protein synthesis of cancer cells.
We previously reported the intimate relationship between VEGF
expression and p53 mutation (Uchida et al, 1998). However, in this
study, we found an inverse correlation between VEGF and
p53 in lymph node metastasis. This finding suggests that VEGF
would be regulated by pathways other than p53 in lymph node
metastasis.
The mechanism of this regulation of VEGF, MMP-9, E-cad-
herin and p53 is unknown. Accumulation of gene abnormalities is
generally thought to provide metastatic potential to cancer cells,
and worsen prognosis (Vogelstein et al, 1989; Bland et al, 1995;
Shimada et al, 1997). However, this study demonstrates that the
acquired expression of malignant factors is not maintained through
the end-stage of metastasis, but in fact changes. As the metastatic
stage in the lymph node is advanced, the normal structure of the
lymph node is gradually destroyed, and function of lymph nodes
might be suppressed or lost. We suggest that the microenvironment
(e.g. extracellular matrix, growth factors, cytokines and host
defence) around cancer cells might change as cancer cells prolif-
erate, and that as a consequence, the interaction between the
cancer cells and the microenvironment might also change. In this
study, we found inter-nodal heterogeneity as well as intra-nodal
heterogeneity. Inter-nodal heterogeneity might be the result of not
only heterogeneity of the cancer cell clones but also the alternative
reaction of cancer cells to different microenvironments.
With regard to the staging of lymph node metastasis, Kurokawa
(1970) divided lymph node metastases into three grades in an
experimental model of lymph node metastasis. Shigetomi et al
(1992) later modified Kurokawa’s classification into four stages by
observation of numerous serial sections, using the staging as an
index of the metastatic potential (i.e. stage 0: cancer cells are
limited in perinodal lymphatic vessels; stage 1: cancer cells are
seen only in peripheral sinus; stage 2: cancer cells invade the
cortex of lymph node, but not beyond 50%; stage 3: more than
50% of lymph node is occupied by cancer cell). However, to the
best of our knowledge, no one has yet reported the correlation
between the expression of cancer-related factors and the extent of
lymph node metastasis. In order to simplify the data, we cate-
gorized the extent of lymph node metastases roughly into two
stages by the space occupation rate of cancer cells (cut-off point:
50%).
From a therapeutic aspect, angiogenesis-mediators and MMPs
have recently been the focus of targeted anticancer therapy (Gastl
et al, 1997). If anti-angiogenesis drugs or MMP inhibitors are to be
used as adjuvant therapy after surgery or therapy for recurrent
tumours, information regarding the angiogenesis-mediators and
MMPs in residual cancer cells will be required to judge the indica-
tion for the therapy. This study suggests that drugs directly
inhibiting VEGF or MMPs might be more effective in micro-
metastasis or in cancer cells in Early Stage than in Late Stage.
In conclusion, the expression of VEGF, MMP-9 and E-cadherin
are down-regulated from Early Stage to Late Stage of lymph node
metastasis. Future analysis of the mechanisms responsible for
these phenomena will be necessary.
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